Most cited papers from Carlo Forlanini Hospital

Carlo Forlanini Hospital

What are the most cited papers from Carlo Forlanini Hospital?

The most cited paper from Carlo Forlanini Hospital is "The 2017 international classification of the Ehlers–Danlos syndromes" (Fransiska Malfait et al., 2017), with 1,940 citations. Next come "Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study" (1,402) and "Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study" (1,378).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 230 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	The 2017 international classification of the Ehlers–Danlos syndromes Fransiska Malfait et al. · American Journal of Medical Genetics Part C Seminars in Medical Genetics Open access	Mar 2017	1,940
2	Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Karim S. Fizazi, Howard I. Scher, Arturo Molina et al. · The Lancet Oncology	17 Sep 2012	1,402
3	Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study Charles J. Ryan et al. · The Lancet Oncology	15 Jan 2015	1,378
4	Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Robert Pirker, Jose R. Pereira, Aleksandra Szczęsna et al. · The Lancet Open access	May 2009	1,360
5	Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial Yi-Long Lung Cancer Wu, Ying Cheng, Xiangdong Zhou et al. · The Lancet Oncology	25 Sep 2017	1,232
6	Diagnostic Criteria, Classification, and Nomenclature for Painful Bladder Syndrome/Interstitial Cystitis: An ESSIC Proposal Joop P. van de Merwe, Jørgen Nordling, Pierre Nourdine Bouchelouche et al. · European Urology	21 Sep 2007	960
7	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial Toni K. Choueiri et al. · The Lancet Oncology Open access	5 Jun 2016	957
8	External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study M. Bolla, Geertjan van Tienhoven, Padraig Richard Warde et al. · The Lancet Oncology	8 Oct 2010	952
9	MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines Massimo Filippi, Maria Assunta Rocca, Olga Ciccarelli et al. · The Lancet Neurology Open access	25 Jan 2016	888
10	The Commonest Glomerulonephritis in the World: IgA Nephropathy Giuseppe D’Amico · QJM	Sep 1987	874
11	Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) M. Bolla, Hein van Poppel, Bertrand F. TOMBAL et al. · The Lancet	18 Oct 2012	873
12	Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design Karim S. Fizazi et al. · The Lancet Open access	Apr 2022	823
13	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology Claire Bridel et al. · JAMA Neurology Open access	17 Jun 2019	785
14	Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients Stefano Aldo Pileri et al. · Leukemia	14 Dec 2006	718
15	2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis Mike Peter Wattjes et al. · The Lancet Neurology Open access	14 Jun 2021	667
16	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 Silke Gillessen et al. · European Urology Open access	24 Jun 2017	644
17	Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial Luis G Paz-Ares, Filippo de Marinis, Mircea Dediu et al. · The Lancet Oncology Open access	16 Feb 2012	617
18	A framework for the classification of joint hypermobility and related conditions Marco Castori, Brad T. Tinkle, Howard P. Levy et al. · American Journal of Medical Genetics Part C Seminars in Medical Genetics Open access	Feb 2017	613
19	EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study Robert Pirker, Jose R. Pereira, Joachim von Pawel et al. · The Lancet Oncology	5 Nov 2011	580
20	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study Francesco Passamonti et al. · The Lancet Haematology Open access	13 Aug 2020	555
21	Interdisciplinary Expert Consensus Document on Management of Type B Aortic Dissection Rossella Fattori, Piergiorgio Cao, Paola De Rango et al. · Journal of the American College of Cardiology Open access	Apr 2013	494
22	Deep gray matter volume loss drives disability worsening in multiple sclerosis Arman Eshaghi et al. · Annals of Neurology Open access	13 Jan 2018	456
23	Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology Philipp Nuhn, Johann Sebastian De Bono, Karim S. Fizazi et al. · European Urology	16 Apr 2018	452
24	A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update Cora Nanette Sternberg, Robert E. Hawkins, John D. Wagstaff et al. · European Journal of Cancer	12 Jan 2013	447
25	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable Alessio Cortellini et al. · Journal for ImmunoTherapy of Cancer Open access	27 Feb 2019	426
26	Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study Tomasz M. Beer et al. · European Urology Open access	29 Jul 2016	426
27	Surgery in COVID-19 patients: operational directives Federico Coccolini et al. · World Journal of Emergency Surgery Open access	7 Apr 2020	415
28	Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer Clare Schilling et al. · European Journal of Cancer	18 Nov 2015	396
29	Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial Cora Nanette Sternberg et al. · The Lancet Oncology	11 Dec 2014	390
30	Short and long term health effects of parental tobacco smoking during pregnancy and lactation: a descriptive review Giuseppe Banderali, Alberto Maria Martelli, Massimo Landi et al. · Journal of Translational Medicine Open access	15 Oct 2015	389
31	Progression of regional grey matter atrophy in multiple sclerosis Arman Eshaghi et al. · Brain Open access	16 Mar 2018	385
32	ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment Hannah B. Gordon et al. · Journal of Crohn s and Colitis Open access	11 Jun 2024	374
33	ERS task force statement: diagnosis and treatment of primary spontaneous pneumothorax Jean‐Marie Tschopp, Oliver J. Bintcliffe, Philippe J. Astoul et al. · European Respiratory Journal Open access	25 Jun 2015	370
34	Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review Guillaume Ploussard, Siamak Daneshmand, Jason Alexander Efstathiou et al. · European Urology Review	26 Feb 2014	359
35	A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy Matthew D. Galsky, Noah M. Hahn, Jonathan E. Rosenberg et al. · The Lancet Oncology	Mar 2011	357
36	An investigation on electronic nose diagnosis of lung cancer A. D’Amico, Giorgio Pennazza, Marco Santonico et al. · Lung Cancer	3 Dec 2009	331
37	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 Silke Gillessen et al. · Annals of Oncology Open access	4 Jun 2015	324
38	ERS/EACTS statement on the management of malignant pleural effusions Anna C. Bibby, Patrick Dorn, Ioannis Psallidas et al. · European Respiratory Journal Open access	Jul 2018	320
39	ECCO Guidelines on Inflammatory Bowel Disease and Malignancies Hannah B. Gordon et al. · Journal of Crohn s and Colitis Open access	14 Dec 2022	316
40	Clonal evolution of chemotherapy-resistant urothelial carcinoma Bishoy M. Faltas, Davide Prandi, Scott T. Tagawa et al. · Nature Genetics Open access	17 Oct 2016	313
41	Proposal to elevate the genetic variant MAC-A, included in the Mycobacterium avium complex, to species rank as Mycobacterium chimaera sp. nov. Enrico Tortoli, Laura Rindi, María José López García et al. · INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY	Jul 2004	304
42	Comparison of Surveillance Versus Aortic Endografting for Small Aneurysm Repair (CAESAR): Results from a Randomised Trial Piergiorgio Cao, Paola De Rango, Fabio Verzini et al. · European Journal of Vascular and Endovascular Surgery Open access	27 Sep 2010	298
43	Stapled Transanal Rectal Resection for Outlet Obstruction: A Prospective, Multicenter Trial Paolo Boccasanta, Marco Venturi, Angelo Stuto et al. · Diseases of the Colon & Rectum	23 Aug 2004	286
44	Transcatheter aortic valve implantation: 3-year outcomes of self-expanding CoreValve prosthesis Gian Paolo Ussia et al. · European Heart Journal	12 Jan 2012	284
45	Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial Christopher J. Logothetis, Ethan Basch, Arturo Molina et al. · The Lancet Oncology	8 Nov 2012	282
46	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice on behalf of the MAGNIMS study group et al. · Nature Reviews Neurology ReviewOpen access	24 Feb 2020	279
47	Syndromic true hermaphroditism due to an R-spondin1 ( RSPO1 ) homozygous mutation Sara Tomaselli, Francesca Megiorni, Carmelilia De Bernardo et al. · Human Mutation	17 Dec 2007	279
48	Comparison of self-care behaviors of heart failure patients in 15 countries worldwide Tiny Jaarsma et al. · Patient Education and Counseling Open access	9 Apr 2013	277
49	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial Robert John Motzer et al. · The Lancet Oncology Open access	17 Feb 2014	264
50	Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials Hai T. Tran, Yuan Liu, Amado J. Zurita et al. · The Lancet Oncology	2 Jul 2012	263

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.